Want to buy a pain therapy? Nektar lays out a PhIII sales pitch
Nektar Therapeutics has a late-stage pain drug to sell to someone. And this morning the San Francisco-based biotech — which has been building a focus on oncology — added a Phase III readout showing NKTR-181’s ability to handily beat out a placebo in treating chronic pain.
The key attraction to this drug, though, is Nektar’s $NKTR billing this therapy as the first mu-opioid agonist to lessen the pain without triggering the euphoria that launched the opioid epidemic in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.